Tirzepatide — sold as Zepbound for weight loss and Mounjaro for diabetes — is the most effective weight-loss medication ever approved: an average of 20 to 22 percent total body weight lost at the highest dose in the SURMOUNT-1 trial, a result approaching bariatric surgery territory. But the medication is only half the treatment. The other half is the program around it — physician evaluation, labs, individualized titration, side-effect management, and an honest exit strategy — and that’s what separates a supervised medical practice from the telehealth scripts flooding this space. At Healthy Life Bariatrics, tirzepatide is prescribed by a surgeon who treats obesity across its full spectrum, which means you get the medication when it’s the right tool and a candid alternative when it isn’t. This page covers how tirzepatide works, real expected results, costs and insurance in 2026, and how our program runs.

How Tirzepatide Works — and Why It Outperforms

Tirzepatide activates two gut-hormone receptors at once: GLP-1 (the target of semaglutide/Wegovy/Ozempic) and GIP. The dual action slows stomach emptying, quiets appetite signaling in the brain, improves insulin sensitivity, and — the part patients describe most vividly — turns down the constant “food noise.” In head-to-head context, semaglutide’s landmark trial produced roughly 15 percent total body weight loss; tirzepatide’s produced 20 to 22 percent. Roughly a third of tirzepatide patients at the top dose lose 25 percent or more — genuinely bariatric-surgery-range numbers, achieved pharmacologically.

The catch nobody should hide from you: the SURMOUNT trials also showed that stopping the medication reverses most of the loss within a year for most patients. Tirzepatide manages obesity; it doesn’t cure it. Any program that doesn’t discuss the long-term plan — maintenance dosing, transition to surgery, or structured lifestyle consolidation — is selling injections, not treatment.

Who Qualifies — and Who Should Consider Surgery Instead

FDA labeling for weight management covers BMI 30+, or BMI 27+ with at least one weight-related condition (hypertension, type 2 diabetes or prediabetes, sleep apnea, dyslipidemia). Contraindications we screen for: personal or family history of medullary thyroid carcinoma or MEN 2 syndrome, prior pancreatitis, active gallbladder disease, and pregnancy or planned pregnancy.

Where the surgical conversation belongs — and where being a surgical practice makes our advice different from a med-spa’s:

• BMI 40+, or 35+ with significant comorbidities — surgery remains the more durable, and usually more economical, primary treatment; medication can bridge or complement it
• Medication plateaus short of your health goals — a sleeve or SADI-S continues where the drug stopped
• The monthly cost is unsustainable — a one-time surgical cost frequently beats years of injections (the arithmetic is on our cost guide)
• You simply prefer a one-time intervention — a legitimate preference we respect in both directions

What Our Supervised Program Actually Includes

• Physician evaluation — full medical history, medication review, and screening for contraindications, by a physician, not an intake form
• Baseline labs — metabolic panel, HbA1c, lipids, thyroid, kidney and liver function — repeated at 3 and 6 months
• Individualized titration — starting at 2.5 mg weekly and stepping up only as tolerance allows; racing to the top dose is the number-one driver of the nausea that makes patients quit
• Monthly check-ins — weight, side effects, dose decisions, and course corrections
• Dietitian support — protein-first eating preserves muscle during rapid loss; this is the difference between losing weight and losing fat
• The exit plan, discussed on day one — maintenance dosing, surgical conversion, or structured tapering; never an open-ended subscription by default

Tirzepatide Cost and Insurance in 2026

• Insured (weight-loss coverage) — roughly 30–45 percent of commercial plans now cover Zepbound with prior authorization; copays commonly run $25–$150/month. Our office handles the PA paperwork and appeals.
• Brand cash-pay — approximately $1,000–$1,300/month at retail; Eli Lilly’s direct-purchase programs offer certain doses lower.
• Medicare — still does not cover GLP-1s for weight loss (diabetes indications differ).
• Compounded tirzepatide — exists at $300–$500/month; quality varies widely and the FDA has warned repeatedly about non-bio-identical products. If a compounded route is considered, it happens with verified pharmacies and full disclosure — and we’ll tell you plainly when we think it’s the wrong call.

Frequently Asked Questions About Our Tirzepatide Program

How much weight will I actually lose on tirzepatide?

Trial averages: 20 to 22 percent of total body weight at the 15 mg dose over 72 weeks — for a 250-pound patient, roughly 50 to 55 pounds. Real-world results track adherence, reached dose, and eating pattern; a third of top-dose patients exceed 25 percent, while patients who stay at lower doses or dose inconsistently land nearer 10 to 15 percent. Expect a steady 4-to-6-month curve of progressive loss rather than a rapid drop — and expect us to adjust the plan monthly based on your actual response.

What are the most common side effects?

Gastrointestinal, mostly during dose increases: nausea (the most common), diarrhea or constipation, and fatigue — affecting roughly half of patients at some point, usually mild and improving as the body adapts. Serious but uncommon risks we screen for and monitor: pancreatitis, gallbladder disease (rapid weight loss raises gallstone risk), and the thyroid contraindications. Slow titration, eating smaller meals, and front-loading protein prevent most quitting-level side effects — this is precisely what the monthly supervision is for.

Tirzepatide vs semaglutide — which should I take?

Tirzepatide produces meaningfully more weight loss on average (20–22 percent vs about 15 percent), which makes it our usual first choice when coverage and budget allow. Semaglutide wins when your insurance covers it and not Zepbound, or when you’ve tolerated it well previously. Both are legitimate; switching between them is straightforward when needed. Our medical director has published a detailed comparison — see the semaglutide vs tirzepatide guide — and we prescribe both, so the recommendation follows your case, not our inventory.

Do I have to stay on tirzepatide forever?

Not necessarily — but stopping cold usually costs most of the result: trial extensions show roughly two-thirds of lost weight returning within a year of discontinuation. The realistic long-term paths are maintenance dosing (lower dose or less frequent), conversion to bariatric surgery once you’ve seen what’s possible, or a structured taper with aggressive lifestyle consolidation for a motivated minority. We map this on day one, because “what happens after” should be part of the prescription, not a surprise at month eighteen.

Can I take tirzepatide after bariatric surgery?

Yes — and this combination is one of the most useful recent developments in obesity medicine. For post-sleeve or post-bypass patients with regain or a stalled plateau, adding tirzepatide frequently restarts meaningful loss without revision surgery, and we often trial it before recommending a surgical conversion. As a practice that performs both the surgery and the prescribing, we can sequence the tools in whichever order your case actually calls for — which sometimes means medication first, surgery later; sometimes the reverse.

Why go through a bariatric practice instead of a telehealth app?

Because the medication is the easy part. The app model ships you a pen after a questionnaire; what it can’t do is examine you, run and interpret labs, manage the gallbladder attack at month four, tell you honestly when surgery would serve you better, or handle the insurance appeal that saves you $1,100 a month. A surgeon-led program treats tirzepatide as one tool in a complete obesity practice — with a direct line to every other option when your response to the first one demands a change of plan.

Start With an Honest Evaluation

Whether tirzepatide, another medication, surgery, or a combination is your best path is a clinical question — one worth answering with a physician who offers all of them. The consultation includes full evaluation, insurance verification for medication coverage, and a written plan with real numbers. Existing patients on Ozempic or semaglutide who are curious about switching: bring your dosing history and we’ll map the transition.

Schedule a consultation: healthylifebariatrics.com/contact · (310) 455-8020

Last updated 2026-07-06. Medically reviewed by Dr. Babak Moeinolmolki, MD, dual board-certified in bariatric and cosmetic surgery.